Different routes for the in vivo administration of synthetic siRNA complexes targeting lung tumors were compared, and siRNA complexes were administered for the inhibition of hypoxia-inducible factor (HIF-1a and HIF-2a). Intravenous jugular vein injection of siRNA proved to be the most effective means of targeting lung tumor tissue in the Lewis lung carcinoma (LLC1) model. In comparison, intraperitoneal injection of siRNA was not suitable for targeting of lung tumor and intratracheal administration of siRNA exclusively targeted macrophages. Inhibition of HIF-1a and HIF-2a by siRNA injected intravenously was validated by immunohistofluorescent analysis for glucose-transporter-1 (GLUT-1), a well-established HIF target protein. The GLUT-1 signal was strongly attenuated in the lung tumors of mice treated with siRNA-targeting HIF-1a and HIF-2a, compared with mice treated with control siRNA. Interestingly, injection of siRNA directed against HIF-1a and HIF-2a into LLC1 lung tumor-bearing mice resulted in prolonged survival. Immunohistological analysis of the lung tumors from mice treated with siRNA directed against HIF-1a and HIF2a displayed reduced proliferation, angiogenesis and apoptosis, cellular responses, which are known to be affected by HIF. In conclusion, intravenous jugular vein injection of siRNA strongly targets the lung tumor and is effective in gene inhibition as demonstrated for HIF-1a and HIF-2a.
Introduction
Inhibition of gene expression by RNA interference has become a well-established tool for functional gene analysis in cell culture studies. Its application for in vivo studies in tumor biology and for a possible therapeutic intervention is a challenging and promising research field. Successful transfection of subcutaneous tumor models has been described for synthetic siRNAs complexed with polyethylenimine (PEI) that were administered intraperitoneally. 1 The feasibility of this and other routes of administration for targeting lung tumors by siRNA has not been investigated.
In an earlier study, we described a lung-specific tumor model employing Lewis lung carcinoma cells (LLC1), which were instilled into the trachea. 2 In this model, we demonstrated that tumor vascularization arises primarily from the pulmonary artery. This model has now been employed to compare different routes of in vivo siRNA administration for targeting lung tumors. We analyzed the administration through the jugular vein catheter and compared it with intratracheal and intraperitoneal administration. Fluorescent-labeled siRNA was employed for histological analysis by fluorescence microscopy of cryosections from tumor and organ tissue.
In particular, hypoxia-inducible factors (HIF-1a and HIF-2a) were targeted by siRNA in this model. Hypoxiainducible factors are dimeric transcription factors consisting of an a-and b-subunit. [3] [4] [5] The a-subunit is stabilized and activated under hypoxic conditions, thus HIF mediates adaptive responses of cells to a hypoxic environment and improves cell survival. 6 In solid tumors, hypoxic areas with limited nutrient supply are caused by aberrant angiogenesis which is out of balance with the concomitantly growing tumor, resulting in inadequate tumor perfusion. Anemia may also be observed in cancer, or may be induced by cancer therapy and can further promote hypoxic areas. 7 Activation of HIF also occurs through growth factors and genetic alterations to oncogenes and tumor suppressor genes. 8 Both HIF-1 and HIF-2 induce a heterogeneous group of approxi-mately 100 target genes identified to date. Most of these genes can be activated by a common conserved hypoxiaresponsive DNA element recognized by both HIF-1 and HIF-2. 9 Some target genes have also been described that are differentially regulated by HIF-1 and HIF-2. Furthermore, HIF-2a is highly expressed in the lung and in endothelial cells. [10] [11] [12] The in vivo knockdown of HIF-1a and HIF-2a in experimental tumor models is of interest and importance for the analysis of their role in tumor progression, and may represent a potential therapeutic option.
In this study, different routes of in vivo siRNA administration were assessed for targeting the lung tumor tissue, employing fluorescent-labeled siRNA. Downregulation of HIF-1a and HIF-2a by specific siRNAs was achieved by intravenous injection of siRNA. Inhibition of HIF-1a and HIF-2a in the LLC1 lung tumor resulted in prolonged survival and was related to reduced angiogenesis and tumor cell proliferation.
Materials and methods

Cell culture
The C57BL/6-derived Lewis lung carcinoma cell line (LLC1) was obtained from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI-1640 medium (PAN GmbH, Nu¨rnberg, Germany) supplemented with 5% fetal bovine serum (Greiner BioOne, Frickenhausen, Germany), penicillin (100 U ml
À1
) and streptomycin (0.1 mg ml À1 ) (Greiner BioOne) at 37 1C in humidified atmosphere containing 5% CO 2 in air. A hypoxia environment was prepared in a chamber equilibrated with a humid gas mixture of 1% oxygen, 5% carbon dioxide and 94% nitrogen at 37 1C. Oxygen levels were controlled using a ProOx system (BioSpherix, Ltd., Redfield, NY).
siRNA transfection of cultured cells and in vivo
The siRNAs were synthesized commercially (Biomers.net GmbH, Ulm, Germany): siHIF-1a-forward: GUCACC ACAGGACAGUACAdTdT; siHIF-1a-reverse: UGUA CUGUCCUGUGGUGACdTdT, siHIF-2a-forward: GU CACCAGAACUUGUGCACdTdT, siHIF-2a-reverse: GUGCACAAGUUCUGGUGACdTdT; si-Cy3-forward: UCACCGUCAUCACCACCAUdTdT; si-Cy3-reverse: AUGGUGGUGAUGACGGUGAdTdT; si-control-forward: UAGCGACUAAACACAUCAAdTdT; si-controlreverse: UUGAUGUGUUUAGUCGCUAdTdT. Forward and reverse strands were annealed at a final concentration of 40 mM each by incubation at 95 1C for 1 min and at 37 1C for 1 h in annealing buffer (20 mM potassium acetate, 6 mM HEPES-KOH pH 7.4, 0.4 mM magnesium acetate). Cy3 is a fluorescent dye of the cyanine dye family and was chemically linked to both siRNA strands (si-Cy3-forward and si-Cy3-reverse). Cy3 possesses red fluorescence with a maximum absorption of 550 nm and a maximum emission of 570 nm. siRNA-Cy3 was employed for histological analysis in comparison with the siRNA-control that was not labeled by Cy3. In addition, siRNA-control was employed as a negative control in comparison to siHIF-1a and siHIF-2a. The sequence of siRNA-control does not target any gene in the mouse genome and has been tested by micro-array analysis (Dharmacon Inc., Chicago, IL). In cultured LLC1 cells, siRNA (final concentration 100 nM) was transfected with Lipofectamine 2000 (lipofectamine) (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol. After incubation for 24 h in 21% O 2 , 5% CO 2 at 37 1C, cells were used for the various experiments. For siRNA transfection in vivo, siRNA complexed with the cationic polymer in vivo jetPEI (PEI) (BIOMOL GmbH, Hamburg, Germany) was administered by various routes. The nitrogen/phosphate ratio was adjusted to 1:10. In some experiments, siRNA complexed with lipofectamine was employed. In animal experiments, siRNA was administered at a concentration of 25 mg per mouse. The siRNA mixture was injected intratracheally, or intravenously through an implanted jugular vein catheter. The implantation of the jugular vein catheter has been described earlier. 13 Animal experiments C57BL/6N mice (5-7 weeks old) were purchased from Charles River, Germany. They were maintained under pathogen-free conditions and handled in accordance with the European Communities recommendations for animal experimentation.
Tumor models
The LLC1 lung tumor model: Tumorigenicity was assessed by intratracheal instillation of LLC1 cells (1 Â 10 6 cells per 100 ml saline) as described earlier. 2 The experiments were started 6-10 days later. Subcutaneous LLC1 tumor model: Tumorigenicity was assessed by subcutaneous injection of LLC1 cells (5 Â 10 6 cells per 200 ml saline) into mice. The experiments were started when the tumors reached a volume of 100 mm 3 
.
Survival curves LLC1 lung tumor-bearing mice were treated 9 days after tumor initiation by two jugular vein catheter injections of siRNAs complexed with PEI with an interval of 2 days. Subsequently, survival was monitored. Mice were euthanized when they suffered severely from the lung tumor, and were close to death. Survival curves that plot percent survival as a function of time were established using the Kaplan-Meier algorithm (GraphPad Software Inc., San Diego, CA). The survival curves were compared employing the Mantel-Haenszel log-rank test (GraphPad Software Inc., San Diego, CA).
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was employed for cell analysis by flow cytometry, as described earlier. 14 
Flow cytometry
The total BAL fluid was centrifuged, washed with PBS and resuspended in 500 ml 1% BSA in PBS. Cells were directly analyzed using a FACSCanto flow cytometer with the FACSDiVa software package (both from BD siRNA-targeting lung cancer in vivo F Kamlah et al Biosciences). A minimum of 10 000 cells were analyzed per sample. Gates based on forward and side scatter were set to detect the macrophage population. The negative control (siRNA-control transfected animal) were used to set the auto fluorescence of macrophages and compared with the macrophages of the siRNA-Cy3 transfected animal.
RNA extraction and reverse-transcription PCR Total RNA was extracted by the NucleoSpin procedure (NucleoSpin RNA/Protein, Macherey-Nagel, Germany). Total RNA (1 mg) was denatured at 65 1C for 5 min. After cooling on ice, the following components were added to the samples: 4 ml of 5 Â first strand buffer, 2 ml of 40 mM deoxynucleotide mixture, 1 ml of random-hexamer primer, 1 ml of 0.1 M dithiothreitol, 1 ml RNase inhibitor (Peqlab, Erlangen, Germany), 1 ml moloney murine leukemia virus reverse transcriptase (MMLV) (Invitrogen). After 60 min at 39 1C, reverse transcriptase was inactivated by heating the mixture at 96 1C for 2 min. For the negative control, MMLV-RT was omitted. Real-time PCR was performed using the ABI Prism 7300 Detection System (Applied Biosystems, CA, USA) with SYBR-Green as fluorescent dye, enabling real-time detection of PCR products according to the manufacturer's protocol. The cDNA was submitted to real-time PCR using the primer pairs listed below. Cycling conditions were 50 1C for 2 min, 95 1C for 10 min, followed by 45 cycles of 94 1C for 10 s, 54 1C for 10 s, 72 1C for 30 s. For quantification, the target gene was normalized to porphobilinogen deaminase (PBGD) mRNA as a reference. Real-time data are presented as DC t (DC t ¼ C t T À C t R ; C t T : threshold cycle of target gene, C t R : threshold cycle of PBGD). The following primer sets ( þ , forward; À, reverse) were employed: PBGD þ : TGTCTGGTAACGGCAATGCG, PBGDÀ: CCCACGCGAATCACTCTCAT; HIF-1a þ : TGGTCTAGACAGTGAAGATGAGATG; HIF-1aÀ: TGTGTGTAAGCATTTCTCTCATTTC; HIF-2a þ : GA CGGTGACATGATCTTTCTGTC; HIF-2aÀ: CACTT CATCCTCATGAAGAAGTCAC.
Western blot analysis
Cells were lysed in Laemmli sample buffer including 10% dithiothreitol. For electrophoretic separation, samples were heated at 100 1C for 5 min and then loaded onto a 7.5% polyacrylamide gel. Western blot analysis of HIF1a and b-actin was performed with a monoclonal HIF-1a antibody diluted 1:1000 (Novus Biologicals, Littleton) and monoclonal b-actin antibody diluted 1:20 000 (SigmaAldrich Chemie GmbH, Steinheim, Germany) as described earlier. 15 Immunoreactive signals were detected by chemiluminescence (ECL, Amersham, Buckinghamshire, England) using a secondary antibody coupled to horseradish-peroxidase (Pierce Biotechnology, Rockford).
Histological and cytological analysis
Lungs were inflated with Tissue-Tek (Sakura, Tokyo, Japan) in 0.9% NaCl (1:1). Other organs and the subcutaneous tumors were embedded in Tissue-Tek. The tissues were frozen in liquid nitrogen for the preparation of cryosections (5 mm). Cryosections of the lung from the LLC1 tumor cancer model were stained with hematoxylin-eosin. The cryosections of Cy3-transfected organs and tumors were fixed and stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) as described below. For immunofluorescent staining, the slides were fixed with methanol and acetone (1:1) for 10 min, and washed 3 Â with PBS containing 0.1% BSA and 0.2% Triton X-100. The unspecific binding sites were blocked with 3% BSA in PBS for 1 h. The primary antibodies were applied to the sections or chamber slides at a concentration of 1:100 and incubated for 2 h. After washing, secondary antibodies were incubated for 1 h at a concentration of 1:1000 at room temperature. Counterstaining of the nuclei was performed with 1 mM DAPI (Sigma-Aldrich Chemie GmbH, Munich, Germany) for 10 min. The following primary antibodies were employed: rabbit anti-caspase-3 (Promega Corporation, Madison, WI); rat anti-mouse Ki67 (DAKO Deutschland GmbH, Hamburg, Germany); rat anti-mouse CD31 (Becton Dickinson Labware, Becton Dickinson and Company, Franklin Lakes); rabbit anti-glucose-transporter-1 (GLUT-1) (Abcam Ltd. Cambridge, UK). Goat anti-rabbit-Alexa 555 and goat anti-rat-Alexa 555 (Molecular Probes, Eugene) were employed as fluorescent-conjugated secondary antibodies. Immunofluorescent microscopy was performed with the Leica DMLA Q550/W microscope (Leica Microsysteme Vertrieb GmbH, Bensheim, Germany) and Leica Q-Win standard software for quantification of the signal. The respective signals were measured and related to the DAPI signal from the respective areas. Five representative sections were evaluated for each condition.
Results
The aim of our study was to target lung tumor tissue by synthetic siRNA. We compared different routes of siRNA administration employing fluorescent-labeled siRNA (siRNA-Cy3) for in situ detection by histological fluorescent microscopy. We compared injection of siRNA into the trachea, or administered intraperitoneally or intravenously into the jugular vein by an implanted catheter. Initially, siRNA was injected as a complex with PEI, into the trachea of healthy mice. This approach resulted in the rapid death of the mice. Therefore, intratracheal administration of siRNA complexed with lipofectamine was attempted. Using this methodology, mice survived and fluorescent siRNA was recovered primarily from the airfilled areas of the alveoli, within isolated cells (Figure 1a For verification of the inhibition of HIF-1a and HIF2a in the in vivo experiments, GLUT-1 was selected, as GLUT-1 is a hypoxia-dependent marker that is dependent upon both HIF-1 and HIF-2 for regulation. Furthermore, GLUT-1 can be reliably detected by immunocytofluorescent or immunohistofluorescent microscopy. In the cell culture experiments, combined transfection of LLC1 cells with siHIF-1a and siHIF-2a strongly reduced the GLUT-1 signal when compared with cells treated with the si-control (Figure 5a ). The inhibition of GLUT-1 by siHIF-1a and siHIF-2a was observed under normoxic conditions and hypoxic conditions. The siRNA-targeting lung cancer in vivo F Kamlah et al induction of GLUT-1 under hypoxic conditions was clearly evident. Next, GLUT-1 staining was assessed after in vivo jugular vein catheter injection of siHIF-1a and siHIF-2a. Strongly reduced GLUT-1 signals were observed in cryosections from LLC1 lung tumors, when compared with those treated with si-control (Figures 5b and c) . These results demonstrate that intravenous injection of siRNA worked efficiently when applied for inhibition of HIF-1a and HIF-2a in LLC1 lung tumors.
The progression of LLC1 lung tumors in mice after in vivo treatment with siHIF-1a and siHIF-2a was then assessed, and compared with mice treated with si-control. Nine days after tumor initiation, siHIF-1a and siHIF-2a or si-control were injected intravenously, two times with an interval of 2 days. Subsequently, mice survival was monitored. Interestingly, survival was significantly prolonged in the siHIF-1a-and siHIF-2a-treated mice (Figure 6a ). For further characterization of the effects of siHIF-1a and siHIF-2a treatment, angiogenesis, proliferation and apoptosis were assessed. The CD31 staining of endothelial cells indicating angiogenesis was reduced in the LLC1 lung tumors from the siHIF-1a-and siHIF-2a-treated mice. A reduction in staining for caspase-3 indicating apoptosis and Ki67 indicating proliferation was observed (Figures 6b and c) .
Discussion
In this study, different routes of in vivo siRNA administration were assessed, with the primary aim being to attain transfection of lung tumor tissue in an LLC1 tumor model. We compared intratracheal, intraperitoneal and intravenous injection of fluorescent-labeled siRNA and analyzed its distribution within the healthy lung, the lung tumor tissue and other organs.
The results revealed that (1) intravenous injection of siRNA complexed with PEI by jugular vein catheter was appropriate for targeting the lung tumor tissue. Other organs and tissues studied were not affected by this route. (2) Intratracheal injection of siRNA in complex with lipofectamine primarily targeted lung macrophages, whereas siRNA in complex with PEI was lethal for the mice. In addition, (3) jugular vein catheter administration of siHIF-1a and siHIF-2a strongly suppressed the HIF-1-and HIF-2-dependent GLUT-1 in the lung tumor tissue, as assessed by immunohistofluorescent microscopy. Furthermore, the consequence of HIF-1a and HIF-2a inhibition with regard to tumor progression in the LLC1 lung tumor model was assessed. It was evident that (4) proliferation and angiogenesis were significantly inhibited in siHIF-1a-and siHIF-2a-transfected lung tumors. This was accompanied by prolonged survival of the mice. ). Administration of naked siRNA has been performed by high pressure tail vein injection. This has been performed both in the context of Fasmediated apoptosis in acute liver failure, and to inhibit hepatitis virus B replication. [17] [18] [19] This approach primarily targeted the liver. Other organs investigated, particularly the lung, were less affected by siRNA employing this approach. A disadvantage of this procedure is that it is accompanied by strong volume loading, and it is not suitable for therapeutic approaches. Further approaches with naked siRNA comprise local administration, for example, intradermal, intranasal, subretinal, intraocular and intratumoral injection or direct injection into the liver. Intratracheal injection for directly targeting the lung with naked siRNA in a model of septic acute lung injury has been performed. 20 This study used high amounts of siRNA (75 mg) compared with our study (25 mg). One major disadvantage of applying naked siRNA is that the siRNA is not protected from nuclease degradation by RNase and nucleases within the blood. Furthermore, the cellular uptake of siRNA occurs spontaneously only at low levels, and can be facilitated by chemical transfection procedures, a principle that is well known from established DNA and RNA transfection techniques in cultured cells. Therefore, our studies were performed with complexes of siRNA and cationic polymers (PEI) or cationic lipids (lipofectamine) for stabilization of siRNA, and enhancement of cellular siRNA uptake. However, in our experiments, intratracheal injection of PEI-complexed siRNA was lethal for mice. Toxic effects of PEI in lung have been described.
1 Therefore, we also tested intratracheal administration of siRNA complexed with lipofectamine. In this case, mice survived, however, siRNA uptake was observed almost exclusively in macrophages, as determined by flow cytometry of cells from bronchoalveolar lavages.
Our approach targeting the lung by intravenous (jugular vein) injection with siRNA in a complex with either PEI was the most successful in achieving distribution to all parts of the lung. Vessels, bronchi and cells of the alveolar septum, most likely presenting pneumocytes, were all targeted ( Figure 3 ). This approach appeared to specifically target the lung tumor, as all other organs investigated did not exhibit fluorescent signals, with the exception of some spleen cells when a five-fold higher dose of siRNA complexed with PEI was injected. Interestingly, fluorescent siRNA signals were stronger in lung tumor tissue when compared with the healthy lung tissue. Particularly, tumor areas adjacent to vessels as well as small tumors displayed strong signals (Figure 3 ). In this regard, an earlier study of our group has shown that the pulmonary artery plays a major role in delivering blood supply to LLC1 lung tumors. 2 This finding is in accordance with the observation that jugular vein catheter injection of PEI-complexed siRNA is particularly appropriate for targeting of lung tumor tissue through the pulmonary artery. The finding that LLC1 lung cancer tissue was transfected by siRNA with a higher efficiency than healthy lung tissue is most likely because of anatomical and functional changes to the tumor vessels. 7 These vessels exhibit structural deficiencies, with fenestrations resulting in leakiness which may facilitate the escape of siRNA to tumor cells. In comparison, the intraperitoneal injection of siRNA in a complex with PEI for gene inhibition in subcutaneous tumor models has been described. 1 Intraperitoneal administration was included in this study as a reference technique. However, it appeared unsuitable for targeting of the lung tumor tissue. Intraperitoneal injection of siRNA may have the disadvantage that not all siRNA is taken up by the circulation and thus a considerable amount of injected siRNA is lost. However, intravenous injection of siRNA by jugular vein catheter may have the advantage that the injected siRNA is passing the lung circulation much more concentrated because of limited dilution when compared with intraperitoneal injection. A second advantage may be the diminished possibility for siRNA to adhere to blood vessel walls prior to entering the pulmonary artery.
Jugular vein catheter injection of siRNA was applied for the inhibition of HIF-1a and HIF-2a in the LLC1 lung tumor model. Both HIF subtypes were simultaneously inhibited, as HIF-1 and HIF-2 share common target genes 6 including GLUT-1, 21, 22 which was employed Furthermore, HIF-dependent induction of ATP-generating metabolic pathways adapts cells to the limited oxygen and nutrient supply. In this respect, various levels are affected, such as glucose uptake (by GLUT-1), 21, 22 enhancement of expression or activity of glycolytic enzymes that convert glucose to pyruvate, and further siRNA-targeting lung cancer in vivo F Kamlah et al to lactate by LDH-A. [24] [25] [26] At the mitochondrial level, pyruvate uptake is attenuated and mitochondrial respiration at complex IV is optimized for hypoxic conditions. 24, 25, 27 The overall increase in ATP generation by glycolysis directs metabolism in favor of tumor cell proliferation. At the paracrine level, HIF induces various siRNA-targeting lung cancer in vivogrowth factor and receptor systems (for example, VEGF, VEGFR2, angiopoetins and ephrins), which initiate and maintain angiogenesis. 28 After inhibition of HIF-1a and HIF-2a by siRNA in vivo, a strong downregulation of GLUT-1 in the tumor tissue was observed, as well as in the cell culture experiments. Interestingly, mice with LLC1 lung tumors treated with siHIF-1a and siHIF-2a displayed significantly prolonged survival. Histological analysis of the tumors revealed attenuated proliferation and angiogenesis as possible causes for prolonged survival.
GLUT
Differential effects exerted by either HIF-1a or HIF-2a in tumor growth have not been addressed in this study (for review see Gordan et al. 29 ). Also, effects which were mediated by downregulation of HIF-1a and HIF-2a in either endothelial cells or tumor cells cannot be distinguished by this study, as both cell types were targeted by siRNA. In this respect, two other studies warrant mention. The specific disruption of HIF-1a in endothelial cells generated mice which exhibited normal vascular development. 30 However, angiogenesis of solid tumors was strongly inhibited, most likely because of downregulation of VEGF and VEGFR2. In another study, a dominant-negative HIF-2a was employed for the inhibition of both HIF-1 and HIF-2 in endothelial cells. 31 These mice exhibited lethal cardiovascular defects during embryogenesis. Thus, both studies demonstrated that HIF-1a and HIF-2a expressed in endothelial cells are essential for induction of angiogenesis during development and for tumor angiogenesis.
Taken together, our study revealed that jugular vein catheter injection of siRNA in complex with PEI was a successful route for targeting lung tumor tissue by synthetic siRNA. To our knowledge, this is the first study that reports in vivo transfection of synthetic siRNA for gene inhibition in a lung tumor. This strategy was applied for the inhibition of both HIF-1a and HIF-2a, which resulted in prolonged survival of the tumor-bearing mice, an effect attributed to decreased cell proliferation and angiogenesis.
